BlossomHill Therapeutics Announces Upcoming Presentation for BH-30236, an Oral Macrocyclic CLK Inhibitor, at the 68th American Society of Hematology (ASH) Annual Meeting
Key Highlights
- ➤ASH poster presentation for BH-30236 scheduled December 14, 2026, 7:00-9:00 pm ET
- ➤BH-30236 is in Phase 1/1b trial for R/R AML and HR-MDS
- ➤FDA granted BH-30236 orphan drug designation for AML
- ➤BH-30643 received Fast Track designation for EGFR C797S-resistant NSCLC
Expert Statements
J. Jean Cui, Ph.D., Chief Executive Officer of BlossomHill Therapeutics
“The findings to be presented at ASH provide important clinical validation of BH-30236's mechanism of action and reinforce our confidence in its potential to address significant unmet needs in R/R AML and HR-MDS. We are particularly encouraged by the consistency of the pharmacodynamic effects from preclinic to clinic and we look forward to advancing our CLK program.”
SAN DIEGO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced an upcoming poster presentation highlighting preclinical and clinical data for BH-30236 at the 68th American Society of Hematology (ASH) Annual Meeting, being held December 12-15, 2026, in New Orleans, Louisiana.
BH-30236 is a novel, orally bioavailable, macrocyclic CDC-like kinase (CLK) inhibitor that modulates aberrant alternative pre-mRNA splicing, a defining feature implicated in cancer progression and therapeutic resistance across both hematologic malignancies and solid tumors. BH-30236 is currently being evaluated in a Phase 1/1b multicenter, open-label, first-in-human dose escalation and expansion trial in adults with relapsed or refractory (R/R) acute myeloid leukemia (AML) and higher-risk myelodysplastic syndrome (HR-MDS).
Get started
Create a free account to read the full story.